“…In some clinical trials, the doses of 5 mg or 10 mg daily or 30 mg, 50 mg, or 70 mg weekly were used. In the others, the dose was titrated to achieve serum concentrations of 3 to 5 ng/mL, 5 to 10 ng/mL, and up to 5 to 15 ng/mL [20,21,24]; moreover, this is not compatible with dosing recommendations in transplant recipients and might potentially limit expected benefits in TSC patients. The rapamycin data show that "the immunosuppressive dosage" after kidney transplantation can be beneficial to TSC manifestations [13e18].…”